

**Brighton and Sussex University Hospitals NHS Trust  
Clinical Trials Delivery Performance Q3 2020 to 2021**

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/LO/0928	170943	Mitral Valve Repair Clinical Trial (MAVERIC Trial)	Number Agreed	5	5	Date Agreed	31/03/2017	5	20/02/2020	5	Recruitment Finished
19/YH/0151	257273	B7981015 - PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA)	Number Agreed	4	4	Date Agreed	31/03/2020	8	01/03/2020	8	Recruitment Finished
19/LO/0496	259483	A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis.	Number Agreed	4	4	Date Agreed	01/03/2020	3	31/03/2020	3	Recruitment Finished
17/SW/0255	234748	Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System	Number Agreed	4	4	Date Agreed	31/08/2018	0	25/02/2020	4	Recruitment Finished
19/LO/1217	264929	Watchman FLX Left Atrial Appendage Closure Device Post Approval Study	Range Agreed	5	20	Date Agreed	01/11/2020	12	22/06/2020	12	Recruitment Finished
17/EM/0121	221773	A Study To Investigate The Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)	Range Agreed	3	5	Date Agreed	31/12/2019	2	30/04/2020	3	Recruitment Finished
18/LO/1187	240011	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy	Number Agreed	3	5	Date Agreed	30/11/2019	5	13/05/2020	5	Recruitment Finished
19/EM/0034	255895	A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of padsevoniil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy	Number Agreed	2	2	Date Agreed	31/08/2020	3	22/05/2020	3	Withdrawn By Sponsor
17/WM/0207	222284	Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation	Number Agreed	10	20	Date Agreed	30/06/2019	10	15/10/2020	10	Recruitment Finished
19/NE/0374	275170	MK8591A-017 study – A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A (Islatravir/Doravirine) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy.	Range Agreed	1	3	Date Agreed	30/09/2020	4	20/08/2020	4	Recruitment Finished
19/SC/0507	265282	RESPOND EDGE: Repositionable Lotus Edge™ Valve System – Post Market Evaluation of Real World Clinical Outcomes	Range Agreed	10	40	Date Agreed	30/06/2022	39	26/08/2020	39	Recruitment Finished
18/EM/0119	244650	Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)	Range Agreed	3	6	Date Agreed	31/12/2019	0	12/06/2020	1	Withdrawn By Host
19/LO/0040	253233	A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED QUALITY OF LIFE	Number Agreed	5	5	Date Agreed	01/02/2020	1	07/09/2020	1	Recruitment Finished
19/SW/0093	260867	A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis	Number Agreed	2	2	Date Agreed	30/06/2020	0	29/10/2020	0	Withdrawn By Host
18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Range Agreed	1	4	Not Available / Not Agreed			16/11/2020	0	Recruitment Finished